High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies.
High-dose etoposide has been added to total body irradiation, cyclophosphamide, carmustine, or busulfan in preparatory regimens for allogeneic or autologous bone marrow transplantation for patients with leukemia, Hodgkin's disease, lymphoma, or multiple myeloma. The treatment results are encouraging, indicating that etoposide may be a valuable addition to the previously established regimens. Etoposide should be incorporated into collaborative, prospective trials to define its ultimate role in bone marrow transplantation.
Blume
K G
KG
Stanford University Medical Center, CA.
Forman
S J
SJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D017024:Chemotherapy, Adjuvant; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D009101:Multiple Myeloma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D014916:Whole-Body Irradiation
D005047:Etoposide